|
|
|
| The Research Progress on Tumor Immune Escape Built in Relations of Tumor and T Lymphocytes |
| CHEN Hai1, MAO Jian-ping 2 |
1. General Hospital of Beijing Military Area Command of Chinese PLA, Beijing 100007, China;
2. Institute of Radiation Medicine, AMMS, Beijing 100850, China |
|
|
|
Abstract Clarifying tumor immune escape is pivotal for preventing, diagnosis and treatment of tumor. Tumor evade immune surveillance was known associated with poor host immune, T cells anergy, deletions or modulations of tumor associate antigens, lack of co-stimulatory pathway signals and others related. The recent research progresses on tumor-T lymphytes relationship by which immune escape happened was summerized, and focused on T-cell recognition and tolerence to tumor, downregulation of recognition molecules caused defective recognition by activated T cells to tumor, tumor resistance to apoptosis, inhibitory receptors and inhibitory molecules induced T cell anergy and tolerability, tumor attack T cells, and tumor suppress by Tregs and MDSCs. It provided a vision to understand tumor immune escape in which immune elimination, immune equilibrium and escape happened, and was significant for understanding immune surveillance mechanism, for tumor therapy.
|
|
Received: 03 July 2012
Published: 25 October 2012
|
|
|
|
|
[1] Ehrlich P, Vber den Jetzigen, Stand der Karzinomforschung. Nederlands Tijdschrift voor Geneeskunde, 1909, 5:273-290.
[2] Rousalova I, Krepela E. Granzyme B-induced apoptosis in cancer cells and its regulation. International Journal of Oncology, 2010, 37(6):1361-1378.
[3] Seliger B, Ruiz-Cabello F, Garrido F. Chapter 7 IFN inducibility of major histocompatibility antigens in tumors. Advances in Cancer Research, 2008, 101:249-276,.
[4] Schreiber R D, Old L J, Smyth M J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 2011, 331(6024):1565-1570.
[5] Palena C, Schlom J. Vaccines against human carcinomas: strategies to improve antitumor immune responses. Journal of Biomedicine and Biotechnology, 2010, Article ID 380697.
[6] Deschoolmeester V, Baay M, Marck V Van, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunology, 2010, 11, article 19.
[7] Kurts C, Robinson B W, Knolle P A. Cross-priming in health and disease. Nature Reviews Immunology, 2010, 10:403-414.
[8] Shen H, Tesar B M, Walker W E, et al. Dual signaling of MYD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. Journal of Immunology, 2008, 181(3):1849-1858.
[9] Barbalat R, Ewald S E, Mouchess M L, et al. Nucleic acid recognition by the innate immune system. Annual Review of Immunology, 2011, 29:185-214.
[10] Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene, 2010, 29(4):482-491.
[11] Manning J, Indrova M, Lubyova B, et al. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology, 2008, 123(2):218-227.
[12] Du Caigan, Wang Yuzhuo.The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp & Clin Can Res, 2011, 30:12-22.
[13] Respa A, Bukur J, Ferrone S, et al. Association of IFN-γsignal transduction defects with impairedHLA class I antigen processing in melanoma cell lines. Clinical Cancer Research, 2011, 17(9):2668-2678.
[14] Clark R A, Huang S J, Murphy G F, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. Journal of Experimental Medicine, 2008, 205(10):2221-2234.
[15] Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Experimental Cell Research, 2010, 316(6):887-899.
[16] Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 2008, 8(6):467-477.
[17] Hazem Ghebeh. The PD-L1/2 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia, 2006, 8(3):190.
[18] Gadiot J, Hooijkaas A I, Kaiser A D M, et al. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer, 2011, 117(10):2192-2201.
[19] Bari M G, Lutsiak M E, Takai S, et al. TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. Cancer Immunology Immunotherapy, 2009, 58(11):1809-1818.
[20] Greenhough A, Smartt H J M, Moore A E, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 2009, 30(3):377-386.
[21] Iero M, Valenti R, Huber V, et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death and Differentiation, 2008, 15(1):80-88.
[22] Löb S, Königsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunology Immunotherapy, 2009, 58(1):153-157.
[23] Yannelli J R, Tucker J A, Hidalgo G, et al. Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer. Oncology Reports, 2009, 22(6):1459-1471.
[24] Rodriguez P C, Hernandez C P, Morrow K, et al. Larginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression. Journal of Immunology, 2010, 185(9):5198-5204. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
